Dynamic Modification of Sphingomyelin in Lipid Microdomains Controls Development of Obesity, Fatty Liver, and Type 2 Diabetes

• Published in: The Journal of biological chemistry 2011-08, Vol.286 (32), p.28544-28555
• Main Authors: Mitsutake, Susumu, Zama, Kota, Yokota, Hazuki, Yoshida, Tetsuya, Tanaka, Miki, Mitsui, Masaru, Ikawa, Masahito, Okabe, Masaru, Tanaka, Yoshikazu, Yamashita, Tadashi, Takemoto, Hiroshi, Okazaki, Toshiro, Watanabe, Ken, Igarashi, Yasuyuki
• Format: Article
• Language: English
• Subjects: Animals; Caveolae; Caveolae - metabolism; Caveolae - pathology; Caveolin 1 - genetics; Caveolin 1 - metabolism; CD36 Antigens - genetics; CD36 Antigens - metabolism; Ceramide; Ceramides - genetics; Ceramides - metabolism; Diabetes Mellitus, Type 2 - chemically induced; Diabetes Mellitus, Type 2 - genetics; Diabetes Mellitus, Type 2 - metabolism; Diabetes Mellitus, Type 2 - pathology; Dietary Fats - adverse effects; Dietary Fats - pharmacology; Fatty Liver - chemically induced; Fatty Liver - genetics; Fatty Liver - metabolism; Fatty Liver - pathology; Hep G2 Cells; Humans; Insulin Resistance - genetics; Insulin Resistance - radiation effects; Lipid Droplet; Lipid Raft; Lipids; Membrane Lipids; Membrane Proteins - genetics; Membrane Proteins - metabolism; Metabolic Syndrome; Mice; Mice, Knockout; Mice, Obese; Nerve Tissue Proteins - genetics; Nerve Tissue Proteins - metabolism; Obesity - chemically induced; Obesity - genetics; Obesity - metabolism; Obesity - pathology; Sphingolipid; Sphingomyelin; Sphingomyelin Synthase; Sphingomyelins - genetics; Sphingomyelins - metabolism; Transferases (Other Substituted Phosphate Groups) - genetics; Transferases (Other Substituted Phosphate Groups) - metabolism
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1074/jbc.M111.255646

Lipid microdomains or caveolae, small invaginations of plasma membrane, have emerged as important elements for lipid uptake and glucose homeostasis. Sphingomyelin (SM) is one of the major phospholipids of the lipid microdomains. In this study, we investigated the physiological function of sphingomyelin synthase 2 (SMS2) using SMS2 knock-out mice, and we found that SMS2 deficiency prevents high fat diet-induced obesity and insulin resistance. Interestingly, in the liver of SMS2 knock-out mice, large and mature lipid droplets were scarcely observed. Treatment with siRNA for SMS2 also decreased the large lipid droplets in HepG2 cells. Additionally, the siRNA of SMS2 decreased the accumulation of triglyceride in liver of leptin-deficient (ob/ob) mice, strongly suggesting that SMS2 is involved in lipid droplet formation. Furthermore, we found that SMS2 exists in lipid microdomains and partially associates with the fatty acid transporter CD36/FAT and with caveolin 1, a scaffolding protein of caveolae. Because CD36/FAT and caveolin 1 exist in lipid microdomains and are coordinately involved in lipid droplet formation, SMS2 is implicated in the modulation of the SM in lipid microdomains, resulting in the regulation of CD36/FAT and caveolae. Here, we established new cell lines, in which we can completely distinguish SMS2 activity from SMS1 activity, and we demonstrated that SMS2 could convert ceramide produced in the outer leaflet of the plasma membrane into SM. Our findings demonstrate the novel and dynamic regulation of lipid microdomains via conformational changes in lipids on the plasma membrane by SMS2, which is responsible for obesity and type 2 diabetes.